Supplementary material

Supplementary Figure 1. Further details of the HMPS duplication. (a) Oligonucleotide array-CGH analysis of the region around the HMPS duplication.
Position on chromosome 15 is shown on the X-axis. Copy number is shown on the Y-axis. The region of copy number gain is indicated by the red bar. Note the small gaps in coverage owing to failure of probe design in regions of simple repeat sequence. Note also the large proximal gap in coverage in a complex repeat region subsequently shown to lie outside boundaries of the minimal HMPS haplotype.
(b) PCR-based test for the HMPS duplication.
PCR amplification from genomic DNA of a 435bp control region upstream of GREM1 (left) and of a specific 190bp across the duplication boundary (right) are shown. Lane 1, 1kb marker ladder; Lanes 2 and 3, HMPS patients; Lanes 4, 5 and 6, non-HMPS individuals; Lane 7, blank. PCR primers are shown in Supplementary Table 1.   435bp 190bp
Supplementary Figure 2. HMPS pedigrees studied, showing clinical features.
The upper pedigree is from the family that defined the minimal HMPS haplotype. The lower pedigree is that of the patient identified from the CORGI study. Although individual phenotypic data are shown below, we generally classified individuals as affected if they had had multiple (>3) colorectal adenomas, including serrated polyps with adenomatous areas, a definition previously used in our linkage analysis studies (Jaeger et al, Am. J. Hum. Genet. 72: 1261 -1267 , 2003 . This definition was used with the aim of minimising phenocopies and therefore some family members with the HMPS haplotype and duplication were formally defined as non-affecteds, generally owing to their young age or to incomplete medical records in older generations. Details of the other pedigrees we have studied can be found in: Thomas et al, Am. J. Hum. Genet. 58: 770-776, 1996; Whitelaw et al, Gastroenterology, 112: 327-334, 1997; Tomlinson et al, Gastroenterology, 116: 789-795, 1999; and Jaeger et al, Am. J. Hum. Genet. 72:1261 -1267 , 2003 .
Supplementary Figure 3. UCSC Genome Browser display highlighting putative regulatory elements within the HMPS duplication.
The start of the GREM1 transcribed sequence is also shown. Annotation can be found at http://genome.ucsc.edu/. Evidently, such data are not derived from normal colorectal tissue and must therefore be regarded as indicative only.
Supplementary Figure 4. Decreased PTEN expression in HMPS polyps.
In the upper panels, canonical BMP targets are assessed. There is normal expression of phospho-SMAD1,5,8 in non-dysplastic (Aii) and dysplastic (Bii) crypts from HMPS patients (controls not shown). ID1, ID2 and ID3 mRNA expression in normal HMPS crypts is not elevated compared with controls (Cii). In the lower panels, non-canonical BMP targets are assessed. Partial or complete loss of PTEN expression is typically seen in a variable proportion of individual non-dysplastic (Bi) and dysplastic (Bii) crypts from HMPS patients (controls not shown). Overall, of the dysplastic lesions, there was 1 polyp with retained PTEN expression, 4 polyps with generally decreased expression and 3 polyps with patchy total loss of PTEN. These changes in PTEN were associated with increases in the downstream effector AKT (Biii) in individual polyps, although there was not a perfect spatial overlap. The GREM1-positive colon cancer cell line SW948, chosen for its endogenous GREM1 expression and generally high transfection efficiency, was transiently transfected with a pGL3-promoter vector, in which a 4,050 bp stretch of DNA (chr15:30, 778, 782, 505 ) from within the duplicated region was cloned in upstream of the promoter, in order to test its ability to enhance luciferase expression activity. The fragment from the HMPS duplication led to a statistically significant increase in luciferase activity when compared to cells transfected with a control plasmid that showed very similar transfection efficiency (details in Materials and Methods). Interestingly, the region appeared to maintain its enhancer function when it was cloned in reverse orientation. 
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